Engineering >

2024 , Vol. 32 >Issue 1: 14 - 17

DOI: https://doi.org/10.1016/j.eng.2023.10.003

Views & Comments

Strategy for Viral Safety Risk Reassessment with Changes in the Manufacturing Process of Recombinant Biotechnology Products

Expand

  • Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China

Published date: 05 Jan 2024

Fold

Cite this article

Wenbo Sai,Dongchen Jia,Hao Chen,Wei Wei . Strategy for Viral Safety Risk Reassessment with Changes in the Manufacturing Process of Recombinant Biotechnology Products[J]. Engineering, 2024 , 32(1) : 14 -17 . DOI: 10.1016/j.eng.2023.10.003

Options
Outlines

/

〈 〉